Katerina Gurova, MD, PhD
Department of Cell Stress Biology
Roswell Park Cancer Institute

Dr. Katerina Gurova comes to Roswell Park Cancer Institute (RPCI) from Cleveland BioLabs, where she served as Director of Anti-Cancer Drug Discovery. Before joining Cleveland BioLabs, she worked as a Project Scientist in the Department of Molecular Genetics at The Cleveland Clinic.

Dr. Gurova earned her medical degree from the Sechenov Medical Academy and a doctoral degree in experimental oncology from the Blokhin Cancer Research Center, both located in Moscow, Russia. She is a member of the American Association for Cancer Research and authored several research articles and reviews on the mechanisms of cancer cell death.

Dr. Gurova’s research interests are focused on the discovery and development of new anticancer drugs. Specifically, she identified a new class of prospective anticancer agents named curaxins which are capable of simultaneous targeting of several signal transduction pathways that are frequently deregulated in cancer, including p53 and NF-kappaB. Her laboratory at RPCI will be working on decipherine molecular mechanisms, optimizing therapeutic properties of curaxins and on the development of new approaches to treatment of hormone-refractory prostate cancer.